Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.

"Declarations Ethics approval and consent to participate: Not applicable.Consent for publication: Not applicable.Author contributions:Guilherme Nader-Marta: Conceptualization; Methodology; Project administration; Writing – original draft.Chiara Molinelli: Conceptualization; Methodology; Writing – original draft.Véronique Debien: Conceptualization; Methodology; Visualization; Writing – original draft.Diogo Martins-Branco: Conceptualization; Methodology; Writing – review & editing.Philippe Aftimos: Methodology; Resources; Writing – review & editing.Evandro De Azambuja: Methodology; Resources; Supervision; Writing – review & editing.Ahmad Awada: Conceptualization; Methodology; Project administration; Resources; Supervision; Writing – review & editing.Funding: The authors received no financial support for the research, authorship, and/or publication of this article.Competing interests: GNM: Travel grants from Roche, AstraZeneca and Bayer. CM: Honoraria from Novartis and Lilly. VD: None. DMB: Honoraria from Daiichi Sankyo, Novartis, Merck Sharp & Dohme, Janssen, Pfizer, Angelini, and AstraZeneca; meeting/travel grants from Novartis, Merck Sharp & Dohme, LEO Farmacêuticos, Ipsen, Janssen, Roche, Laboratórios Vitória, and Gilead Sciences; institutional grants from Novartis and F. Hoffmann-La Roche Ltd. PA: Consulting: Boehringer Ingelheim, Macrogenics, Roche, Novartis, Amcure, Servier, G1 Therapeutics, Radius, Deloitte; Honoraria: Synthon, Amgen, Novartis, Gilead; Travel grants: Amgen, MSD, Pfizer, Roche; and Research funding to my institution: Roche. EdA: reports speaking fee from Lilly; support to attend medical conferences from Lilly, Novartis, Roche, Genetic, and Istituto Gentili. AA: reports support from Roche, Lilly, Amgen, EISAI, BMS, Pfizer, Novartis, MSD, Genomic Health, Ipsen, AstraZeneca, Bayer, LEO Pharma, Merck, Daiichi, Seattle Genetics, and Pierre Fabre.Availability of data and materials: Not applicable. Competing interests: GNM: Travel grants from Roche, AstraZeneca and Bayer. CM: Honoraria from Novartis and Lilly. VD: None. DMB: Honoraria from Daiichi Sankyo, Novartis, Merck Sharp & Dohme, Janssen, Pfizer, Angelini, and AstraZeneca; meeting/travel grants from Novartis, Merck Sharp & Dohme, LEO Farmacêuticos, Ipsen, Janssen, Roche, Laboratórios Vitória, and Gilead Sciences; institutional grants from Novartis and F. Hoffmann-La Roche Ltd. PA: Consulting: Boehringer Ingelheim, Macrogenics, Roche, Novartis, Amcure, Servier, G1 Therapeutics, Radius, Deloitte; Honoraria: Synthon, Amgen, Novartis, Gilead; Travel grants: Amgen, MSD, Pfizer, Roche; and Research funding to my institution: Roche. EdA: reports speaking fee from Lilly; support to attend medical conferences from Lilly, Novartis, Roche, Genetic, and Istituto Gentili. AA: reports support from Roche, Lilly, Amgen, EISAI, BMS, Pfizer, Novartis, MSD, Genomic Health, Ipsen, AstraZeneca, Bayer, LEO Pharma, Merck, Daiichi, Seattle Genetics, and Pierre Fabre."

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."